An observational study in Severe Asthma, sponsored by Società Italiana di Allergologia, Asma e Immunologia Clinica. Recruiting at 1 site in Italy. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by Società Italiana di Allergologia, Asma e Immunologia Clinica · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 177 studies in Asthma with a site in Italy — 20 open to participants now, 29 under way, 10 of them phase 3. Asthma · Italy.
Among the 177 studies in Asthma with a site in Italy, this one is the 4th largest by planned enrollment of the 47 observational ones that give a count, is one of 9 that started in 2017, is one of 47 observational ones, reaches primary completion later than 13 of the 28 other live ones, and was the 159th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →20 of the 177 studies in Asthma with a site in Italy are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Italy, United States, Argentina and 11 more countries
Ages 6+
Generate Biomedicines · Sites in Italy, United States, Argentina and 16 more countries
Ages 12–80
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 6–17
Pfizer · Sites in Italy, United States, Argentina and 12 more countries
Ages 18–75
AstraZeneca · Sites in Italy, United States, Argentina and 18 more countries
Ages 18–75
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 13 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
177 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 9 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 402 across the 130 interventional studies, 152 across the 47 observational. Of the 136 that completed or were terminated, 66 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 177 have an industry lead sponsor. The 10 most frequent:
Società Italiana di Allergologia, Asma e Immunologia Clinica is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Società Italiana di Allergologia, Asma e Immunologia Clinica has 1 study filed under Asthma — fewer than ten, so there is no comparison to draw.
10 of the studies in Asthma with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT04442646Istituti Clinici Scientifici Maugeri SpARole of "Asthma School" in Disease Management | 2026-12-15 |
| NCT06625216Società Italiana di Allergologia, Asma e Immunologia ClinicaSevere Asthma Network Italy | 2027-02-17 |
Add all 10 to your calendar (.ics) → With an account.
Among the 177 studies in Asthma with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this registry is collecting data of severe asthma patients, recruited by specialized centers, in a real life setting, homogeneously placed on a database management system to follow them over the time.
The information recorded will provide:
Patients older than 12 years, diagnosed for severe asthma by a specialist, according to the ERS/ATS criteria, attending respiratory or allergy clinic for a scheduled visit are eligible for study enrollment. If inclusion/exclusion criteria are satisfied, a written consent to participate in the study will be obtained and an informative leaflet for the patient and his/her GPs will be delivered.
Inclusion Criteria:
diagnosis of severe asthma according to the ERS/ATS criteria:
During treatment with:
at least one of the following occurs or would occur if treatment would be reduced:
Exclusion Criteria have not been considered in order to have a realistic view of severe asthma in real life.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Analyzing epidemiological and clinical characteristics of severe asthmatics from SANI registry.
Collection of sociodemographic data: sex, employment, ethnicity, smocking habits.
Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)
Analyzing epidemiological and clinical characteristics of severe asthmatics from SANI registry.
Collection of clinical data: age, age at asthma onset and/or age at asthma diagnosis (years).
Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)
Analyzing epidemiological and clinical characteristics of severe asthmatics from SANI registry.
Collection of clinical data: weight (kilograms) and height (meters) combined to report Body Mass Index \[BMI\] in kg/m\^2.
Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)
Analyzing epidemiological and clinical characteristics of severe asthmatics from SANI registry.
Collection of clinical data: presence of allergies and/or comorbidities, previous accesses to ER and/or hospitalizations, and numbers of exacerbations.
Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)
Collecting functional data of severe asthmatics from SANI registry.
Assessment of lung function before and after a bronchodilator medication: Forced Vital Capacity \[FVC\] and Forced Expiratory Volume in 1 second \[FEV1\] values (liters) combined to report FEV1/FVC Ratio.
Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)
Collecting functional data of severe asthmatics from SANI registry.
Assessment of lung function before and after a bronchodilator medication: Forced Vital Capacity \[FVC\] and Forced Expiratory Volume in 1 second \[FEV1\] values (percentages) combined to report FEV1/FVC Ratio.
Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)
Assessing inflammatory markers in order to characterize asthma endotypes.
Measurement of Fractional exhaled Nitric Oxide \[FeNO\] (ppb).
Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)
Assessing inflammatory markers in order to characterize asthma endotypes.
Measurement of total serum IgE (kU/L).
Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)
Assessing inflammatory markers in order to characterize asthma endotypes.
Measurement of blood eosinophilia (10\^9 cells/L).
Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)
Assessing inflammatory markers in order to characterize asthma endotypes.
Measurement of blood and sputum eosinophil levels (percentages).
Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)
Assessing asthma control and and PROs.
Assessment of asthma control over time according to the GINA Guidelines and standardized questionnaires: Asthma Control Test \[ACT\], and Asthma Control Questionnaire \[ACQ\].
Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)
Assessing asthma control and and PROs.
Assessment of the quality of life through Asthma Quality of Life Questionnaire \[AQLQ\] .
Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)
Studying the real life efficacy and safety of biologics.
Evaluation of patients' clinical response to each biologics, reports of previous adverse reactions to the drug used and reasons for withdrawal from biologic treatment.
Time frame: through study completion (the length of the follow up for each patient is scheduled for 10 years)
Started Feb 2017 (actual). Primary completion is estimated for Feb 2027, 120 months after the start.
Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 120 months is above that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Società Italiana di Allergologia, Asma e Immunologia Clinica